文献速递妇科

治疗前炎症参数预测子宫内膜癌生存:一项前瞻性数据库分析

Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
PubMed 文献 · Gynecol Oncol · 2021-11-19

本研究前瞻性纳入522例子宫内膜癌患者,分析治疗前全身炎症标志物与生存结局的关系。治疗前CRP≥5.5 mg/L者总生存调整HR=1.68(95%CI 1.00-2.81,p=0.049),癌特异性死亡风险调整HR=2.04(95%CI 1.03-4.02,p=0.04)。绝对淋巴细胞计数、NLR、MLR和SII与不良临床病理因素相关,但与生存无显著关联。

要点

  • 治疗前CRP≥5.5 mg/L与子宫内膜癌总生存和癌特异性生存不良相关。
  • 绝对淋巴细胞计数、NLR、MLR和SII与不良临床病理因素相关,但与生存无显著关联。
  • 作者认为若在独立队列中验证,CRP或可作为简便低成本检测优化治疗前风险评估。

核心结论

  • 治疗前CRP≥5.5 mg/L与子宫内膜癌患者总生存和癌特异性生存不良相关,若在独立队列中验证,CRP或可提供简便低成本检测以优化治疗前风险评估并指导个体化诊疗。

研究设计与样本

  • 前瞻性数据库研究,纳入522例子宫内膜癌女性,中位年龄66岁(IQR 56,73),中位BMI 32 kg/m2(IQR 26,39),多数为低级别(67.2%)、早期(85.4%为I/II期)、子宫内膜样(74.5%)肿瘤,多数为White British族裔。
  • 分析治疗前全身炎症标志物包括C反应蛋白(CRP)、Glasgow预后评分和基于淋巴细胞的比值[中性粒细胞-淋巴细胞比值(NMR)、单核细胞-淋巴细胞比值(MLR)、全身免疫炎症指数(SII)]与总生存、子宫内膜癌特异性生存和无复发生存的关系,采用Kaplan-Meier估计和多变量Cox回归。

主要发现

  • 治疗前CRP≥5.5 mg/L者较CRP<5.5 mg/L者总生存调整HR=1.68(95%CI 1.00-2.81,p=0.049),癌特异性死亡风险调整HR=2.04(95%CI 1.03-4.02,p=0.04)。
  • 绝对淋巴细胞计数、NLR、MLR和SII与不良临床病理因素相关,但在多变量分析中与总生存、癌特异性生存或无复发生存无显著关联。

临床怎么用

  • 作者认为若在独立队列中验证,CRP或可提供简便低成本检测以优化子宫内膜癌治疗前风险评估并指导个体化诊疗。
  • 作者指出参与者多为White British族裔,需进一步研究在其他人群中确认CRP作为预后生物标志物的效用。

局限性

  • 参与者多为White British族裔。
  • 需进一步研究在其他人群中确认CRP作为预后生物标志物的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Inflammation predisposes to tumorigenesis by damaging DNA, stimulating angiogenesis and potentiating pro-proliferative and anti-apoptotic processes. The aim of this study was to investigate whether pre-treatment biomarkers of systemic inflammation are associated with survival outcomes in endometrial cancer. PATIENTS AND METHODS: Women with endometrial cancer were recruited to a prospective database study. Pre-treatment systemic markers of inflammation, including C-reactive protein (CRP), Glasgow Prognostic Score and lymphocyte-based ratios [neutrophil-lymphocyte ratio (NMR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII)], were analysed in relation to overall, endometrial cancer-specific and recurrence-free survival using Kaplan-Meier estimation and multivariable Cox regression. RESULTS: In total, 522 women of mostly White British ethnicity, with a median age of 66 years (interquartile range (IQR), 56, 73) and BMI of 32 kg/m2 (IQR 26, 39) were included in the analysis. Most had low-grade (67.2%), early-stage (85.4% stage I/II), endometrioid (74.5%) tumors. Women with pre-treatment CRP ≥5.5 mg/L had a 68% increase in overall (adjusted HR = 1.68, 95% CI 1.00-2.81, p = 0.049) and a two-fold higher cancer-specific mortality risk than those with CRP <5.5 mg/L (adjusted HR = 2.04, 95%CI 1.03-4.02, p = 0.04). Absolute lymphocyte count, NLR, MLR and SII were associated with adverse clinico-pathologic factors, but not overall, cancer-specific or recurrence-free survival in the multivariable analysis. CONCLUSION: If confirmed in an independent cohort, CRP may offer a simple, low-cost test to refine pre-treatment risk assessment and guide personalised care in endometrial cancer. Our participants were mostly of White British ethnicity and further studies are needed to confirm the utility of CRP as a prognostic biomarker in other populations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Njoku K, Ramchander NC, Wan YL, et al. Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis. Gynecol Oncol. 2021. PMID: 34802721. doi:10.1016/j.ygyno.2021.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。